No US reprieve for Shire's Replagal following new data
This article was originally published in Scrip
Executive Summary
Recently announced one year data show that both treatment naive Fabry disease patients and those switched from Genzyme's Fabrazyme (agalsidase beta) respond well to treatment with Shires own Replagal (agalsidase alfa), says the firm.